GLP-1 Agonists

Eli Lilly

AUDIT: Eli Lilly: The Metabolic Casino: Monetizing the Appetite

An analytical breakdown of Eli Lilly's GLP-1 portfolio, examining how chemical appetite suppression is driving a macroeconomic migration of capital from the global food industry to the pharmaceutical sector amid shifting Medicare coverage.

GLP-1 Agonists

AUDIT: The Paleo Diet: The Biological Short Squeeze

The 2026 Paleo CPG market collapse wasn't just a trend shift; it was a biological margin call. Explore the forensic anatomy of the Ancestral short squeeze.